| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Neoplasms | 82 | 2023 | 4319 | 5.780 |
Why?
|
| Carcinoma, Hepatocellular | 47 | 2023 | 2299 | 4.750 |
Why?
|
| Hepatectomy | 27 | 2021 | 559 | 3.790 |
Why?
|
| Herpesvirus 1, Human | 18 | 2023 | 753 | 3.190 |
Why?
|
| Kidney Transplantation | 94 | 2017 | 4215 | 3.040 |
Why?
|
| Liver Cirrhosis | 30 | 2024 | 1931 | 2.500 |
Why?
|
| Cholangiocarcinoma | 15 | 2021 | 550 | 2.240 |
Why?
|
| Bile Duct Neoplasms | 14 | 2021 | 602 | 2.200 |
Why?
|
| ABO Blood-Group System | 22 | 2015 | 369 | 2.000 |
Why?
|
| Oncolytic Virotherapy | 10 | 2015 | 515 | 1.980 |
Why?
|
| Blood Group Incompatibility | 17 | 2015 | 135 | 1.950 |
Why?
|
| Melanoma | 46 | 2023 | 5697 | 1.900 |
Why?
|
| Graft Survival | 47 | 2016 | 3794 | 1.680 |
Why?
|
| Colonic Neoplasms | 21 | 2014 | 2526 | 1.530 |
Why?
|
| Adenoma, Liver Cell | 2 | 2020 | 32 | 1.420 |
Why?
|
| Graft Rejection | 49 | 2017 | 4426 | 1.420 |
Why?
|
| Hepatic Stellate Cells | 5 | 2024 | 119 | 1.380 |
Why?
|
| Skin Neoplasms | 33 | 2023 | 5799 | 1.360 |
Why?
|
| Liver | 29 | 2024 | 7509 | 1.280 |
Why?
|
| Immunosuppressive Agents | 42 | 2015 | 4166 | 1.220 |
Why?
|
| Sentinel Lymph Node Biopsy | 13 | 2020 | 733 | 1.070 |
Why?
|
| Oncolytic Viruses | 5 | 2015 | 343 | 1.060 |
Why?
|
| Virus Replication | 17 | 2023 | 2432 | 1.020 |
Why?
|
| Tacrolimus | 14 | 2008 | 733 | 1.010 |
Why?
|
| Liver Neoplasms, Experimental | 6 | 2020 | 190 | 0.930 |
Why?
|
| Simplexvirus | 7 | 2012 | 803 | 0.890 |
Why?
|
| Fluorouracil | 11 | 2024 | 1631 | 0.820 |
Why?
|
| Epidermal Growth Factor | 6 | 2016 | 695 | 0.810 |
Why?
|
| Carbon Tetrachloride | 6 | 2024 | 72 | 0.800 |
Why?
|
| Molecular Imaging | 5 | 2020 | 818 | 0.790 |
Why?
|
| Peroxidases | 1 | 2022 | 135 | 0.780 |
Why?
|
| Quinazolines | 5 | 2017 | 1363 | 0.730 |
Why?
|
| Colorectal Neoplasms | 20 | 2023 | 6853 | 0.730 |
Why?
|
| Stomach Neoplasms | 7 | 2017 | 1423 | 0.730 |
Why?
|
| Focal Nodular Hyperplasia | 1 | 2020 | 29 | 0.710 |
Why?
|
| Cyclosporine | 13 | 2000 | 777 | 0.710 |
Why?
|
| Bile Ducts, Intrahepatic | 7 | 2021 | 296 | 0.710 |
Why?
|
| Endostatins | 5 | 2012 | 168 | 0.700 |
Why?
|
| Living Donors | 17 | 2015 | 636 | 0.690 |
Why?
|
| Lymph Nodes | 12 | 2015 | 3486 | 0.660 |
Why?
|
| Humans | 364 | 2024 | 760621 | 0.640 |
Why?
|
| Lymphatic Metastasis | 21 | 2015 | 2943 | 0.630 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 7475 | 0.620 |
Why?
|
| Combined Modality Therapy | 21 | 2023 | 8552 | 0.610 |
Why?
|
| Meningeal Neoplasms | 2 | 2018 | 1249 | 0.600 |
Why?
|
| Flucytosine | 2 | 2011 | 33 | 0.600 |
Why?
|
| Camptothecin | 3 | 2017 | 590 | 0.580 |
Why?
|
| Kidney Failure, Chronic | 9 | 2015 | 2471 | 0.560 |
Why?
|
| Guanidines | 8 | 2000 | 193 | 0.560 |
Why?
|
| Oxonic Acid | 2 | 2017 | 31 | 0.550 |
Why?
|
| Tegafur | 2 | 2017 | 39 | 0.550 |
Why?
|
| Mice, Inbred BALB C | 18 | 2019 | 6216 | 0.550 |
Why?
|
| Prognosis | 46 | 2021 | 29658 | 0.540 |
Why?
|
| Lymph Node Excision | 10 | 2015 | 1303 | 0.540 |
Why?
|
| Animals | 115 | 2024 | 167963 | 0.540 |
Why?
|
| Neoplasms | 21 | 2023 | 22072 | 0.530 |
Why?
|
| Infection Control | 2 | 2020 | 983 | 0.520 |
Why?
|
| Isoantibodies | 6 | 2015 | 661 | 0.520 |
Why?
|
| Portal Vein | 5 | 2023 | 429 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2020 | 9276 | 0.520 |
Why?
|
| Male | 221 | 2024 | 359744 | 0.520 |
Why?
|
| Disease Models, Animal | 26 | 2024 | 18137 | 0.510 |
Why?
|
| Neoplasm Metastasis | 16 | 2021 | 4902 | 0.510 |
Why?
|
| Arteritis | 1 | 2017 | 162 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 9 | 2024 | 5351 | 0.510 |
Why?
|
| Diethylnitrosamine | 6 | 2024 | 45 | 0.510 |
Why?
|
| Tunica Intima | 1 | 2017 | 459 | 0.510 |
Why?
|
| Carcinoma | 9 | 2003 | 2331 | 0.510 |
Why?
|
| Mice | 62 | 2024 | 81208 | 0.500 |
Why?
|
| Tissue Donors | 20 | 2016 | 2313 | 0.490 |
Why?
|
| Tumor Cells, Cultured | 27 | 2015 | 6131 | 0.480 |
Why?
|
| Microvessels | 1 | 2019 | 572 | 0.480 |
Why?
|
| Mice, Nude | 11 | 2024 | 3607 | 0.470 |
Why?
|
| Postoperative Complications | 30 | 2022 | 15697 | 0.470 |
Why?
|
| Survival Rate | 40 | 2019 | 12808 | 0.470 |
Why?
|
| Esophagogastric Junction | 1 | 2016 | 341 | 0.460 |
Why?
|
| Prodrugs | 4 | 2011 | 259 | 0.460 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3085 | 0.460 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3205 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 16 | 2024 | 11712 | 0.450 |
Why?
|
| Breast Neoplasms | 15 | 2023 | 21025 | 0.450 |
Why?
|
| Disease Progression | 16 | 2022 | 13502 | 0.450 |
Why?
|
| Cytosine Deaminase | 2 | 2011 | 65 | 0.440 |
Why?
|
| Manganese | 3 | 2022 | 395 | 0.430 |
Why?
|
| Magnetic Resonance Imaging | 26 | 2024 | 36290 | 0.430 |
Why?
|
| Cell Line, Tumor | 23 | 2024 | 16939 | 0.420 |
Why?
|
| Collagen | 8 | 2023 | 2636 | 0.410 |
Why?
|
| Ulcer | 1 | 2014 | 204 | 0.410 |
Why?
|
| Genetic Vectors | 9 | 2011 | 3380 | 0.410 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 378 | 0.410 |
Why?
|
| Exercise Tolerance | 9 | 2007 | 830 | 0.400 |
Why?
|
| Female | 191 | 2024 | 391270 | 0.400 |
Why?
|
| CD40 Ligand | 1 | 2014 | 521 | 0.400 |
Why?
|
| Fibrosis | 6 | 2024 | 2042 | 0.400 |
Why?
|
| Plasma Cells | 1 | 2015 | 591 | 0.400 |
Why?
|
| Rats | 34 | 2024 | 23711 | 0.400 |
Why?
|
| Aldehydes | 2 | 2023 | 170 | 0.400 |
Why?
|
| Kidney | 16 | 2017 | 7064 | 0.400 |
Why?
|
| Hyaluronic Acid | 5 | 2007 | 482 | 0.400 |
Why?
|
| Follow-Up Studies | 56 | 2020 | 39261 | 0.390 |
Why?
|
| Middle Aged | 159 | 2024 | 220352 | 0.390 |
Why?
|
| Organometallic Compounds | 5 | 2020 | 662 | 0.390 |
Why?
|
| Positron-Emission Tomography | 7 | 2024 | 6465 | 0.390 |
Why?
|
| Carcinoma, Pancreatic Ductal | 5 | 2024 | 1724 | 0.380 |
Why?
|
| Esophageal Neoplasms | 4 | 2016 | 1648 | 0.380 |
Why?
|
| Hepatitis C, Chronic | 6 | 2020 | 1031 | 0.370 |
Why?
|
| Antineoplastic Agents | 18 | 2016 | 13630 | 0.370 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 311 | 0.360 |
Why?
|
| HT29 Cells | 6 | 2014 | 190 | 0.360 |
Why?
|
| Adenocarcinoma | 7 | 2023 | 6315 | 0.360 |
Why?
|
| Desensitization, Immunologic | 1 | 2015 | 534 | 0.350 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2024 | 3584 | 0.350 |
Why?
|
| Vero Cells | 6 | 2014 | 482 | 0.350 |
Why?
|
| Collagen Type I | 3 | 2024 | 616 | 0.350 |
Why?
|
| Adult | 148 | 2022 | 219994 | 0.340 |
Why?
|
| Contrast Media | 8 | 2023 | 5305 | 0.340 |
Why?
|
| Epithelial-Mesenchymal Transition | 4 | 2017 | 730 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2019 | 5643 | 0.330 |
Why?
|
| Gadolinium | 6 | 2021 | 959 | 0.330 |
Why?
|
| Ganciclovir | 3 | 2000 | 252 | 0.330 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 707 | 0.330 |
Why?
|
| Immunity, Cellular | 3 | 2011 | 1557 | 0.320 |
Why?
|
| Transplantation Tolerance | 1 | 2014 | 605 | 0.320 |
Why?
|
| Neoplasm Staging | 22 | 2019 | 11152 | 0.320 |
Why?
|
| Neovascularization, Pathologic | 5 | 2013 | 2640 | 0.320 |
Why?
|
| Time Factors | 59 | 2021 | 40165 | 0.320 |
Why?
|
| Coordination Complexes | 2 | 2021 | 114 | 0.310 |
Why?
|
| Ribonucleosides | 8 | 2005 | 79 | 0.310 |
Why?
|
| Neoplasm Invasiveness | 10 | 2019 | 3618 | 0.310 |
Why?
|
| Thymidine Kinase | 3 | 2023 | 286 | 0.310 |
Why?
|
| Leucovorin | 5 | 2024 | 641 | 0.310 |
Why?
|
| Retrospective Studies | 69 | 2023 | 80372 | 0.310 |
Why?
|
| Histocompatibility Testing | 17 | 2008 | 717 | 0.300 |
Why?
|
| Rats, Wistar | 9 | 2020 | 1850 | 0.300 |
Why?
|
| Cyclosporins | 9 | 1992 | 216 | 0.300 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2023 | 3529 | 0.290 |
Why?
|
| Transgenes | 4 | 2012 | 1006 | 0.290 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 2803 | 0.290 |
Why?
|
| Biopsy | 16 | 2020 | 6771 | 0.280 |
Why?
|
| Electrocoagulation | 3 | 2007 | 152 | 0.280 |
Why?
|
| Aged | 97 | 2024 | 169152 | 0.270 |
Why?
|
| Azathioprine | 11 | 2000 | 356 | 0.270 |
Why?
|
| Anaerobic Threshold | 4 | 1994 | 52 | 0.270 |
Why?
|
| Survival Analysis | 16 | 2020 | 10182 | 0.270 |
Why?
|
| Peptide Fragments | 8 | 2007 | 5125 | 0.270 |
Why?
|
| Oncogenic Viruses | 2 | 2002 | 37 | 0.260 |
Why?
|
| Plasmapheresis | 6 | 2011 | 206 | 0.260 |
Why?
|
| Cytochrome P-450 CYP2B1 | 2 | 2002 | 21 | 0.260 |
Why?
|
| Peritoneum | 1 | 2006 | 224 | 0.260 |
Why?
|
| Europe | 3 | 2021 | 3441 | 0.250 |
Why?
|
| Transplantation Immunology | 4 | 2007 | 532 | 0.250 |
Why?
|
| Antigens, Neoplasm | 2 | 2004 | 1998 | 0.250 |
Why?
|
| Magnesium | 3 | 1998 | 810 | 0.250 |
Why?
|
| Intestinal Absorption | 2 | 2000 | 400 | 0.250 |
Why?
|
| Treatment Outcome | 39 | 2024 | 65017 | 0.250 |
Why?
|
| Receptors, Lymphocyte Homing | 3 | 1995 | 141 | 0.250 |
Why?
|
| Thioacetamide | 1 | 2024 | 22 | 0.250 |
Why?
|
| Gallbladder Neoplasms | 3 | 2011 | 190 | 0.250 |
Why?
|
| Neoadjuvant Therapy | 6 | 2024 | 2821 | 0.240 |
Why?
|
| Catheter Ablation | 5 | 2019 | 2758 | 0.240 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 2009 | 92 | 0.240 |
Why?
|
| Transplantation, Homologous | 12 | 2016 | 4810 | 0.240 |
Why?
|
| Vaccinia virus | 2 | 2003 | 331 | 0.240 |
Why?
|
| Thorium Dioxide | 1 | 2004 | 20 | 0.230 |
Why?
|
| Glycoproteins | 2 | 2010 | 2208 | 0.230 |
Why?
|
| Ribonucleotide Reductases | 2 | 2002 | 76 | 0.230 |
Why?
|
| Methylprednisolone | 12 | 2002 | 384 | 0.230 |
Why?
|
| DNA Methylation | 1 | 2018 | 4373 | 0.230 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2006 | 459 | 0.230 |
Why?
|
| 2-Aminoadipic Acid | 1 | 2023 | 33 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2015 | 929 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 8515 | 0.220 |
Why?
|
| Antigens, CD | 4 | 2013 | 4000 | 0.220 |
Why?
|
| Polymerase Chain Reaction | 12 | 2016 | 6068 | 0.220 |
Why?
|
| Drug Discovery | 3 | 2021 | 1057 | 0.210 |
Why?
|
| Adenoviridae | 3 | 2003 | 1084 | 0.210 |
Why?
|
| Interferon-alpha | 6 | 2014 | 918 | 0.210 |
Why?
|
| Cytomegalovirus Infections | 3 | 1998 | 831 | 0.200 |
Why?
|
| Liver Transplantation | 5 | 2018 | 2325 | 0.200 |
Why?
|
| Heart Transplantation | 2 | 2014 | 3224 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2016 | 15789 | 0.200 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 3696 | 0.200 |
Why?
|
| Alternative Splicing | 6 | 2000 | 1091 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 10 | 2015 | 9185 | 0.200 |
Why?
|
| Indocyanine Green | 1 | 2023 | 236 | 0.200 |
Why?
|
| Captopril | 1 | 2022 | 265 | 0.200 |
Why?
|
| Nucleoside Deaminases | 1 | 2001 | 58 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2009 | 1407 | 0.190 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2021 | 46 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 9411 | 0.190 |
Why?
|
| Mice, Inbred Strains | 3 | 2014 | 1763 | 0.190 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2002 | 618 | 0.190 |
Why?
|
| Magnetite Nanoparticles | 1 | 2023 | 316 | 0.190 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2007 | 615 | 0.190 |
Why?
|
| B-Lymphocytes | 4 | 2011 | 4742 | 0.190 |
Why?
|
| Heart Diseases | 2 | 2014 | 2809 | 0.190 |
Why?
|
| Hepatitis B, Chronic | 1 | 2005 | 403 | 0.180 |
Why?
|
| Spleen | 2 | 2005 | 2298 | 0.180 |
Why?
|
| Drug Therapy, Combination | 17 | 2005 | 6498 | 0.180 |
Why?
|
| Tooth | 2 | 2013 | 208 | 0.180 |
Why?
|
| Sleep Deprivation | 2 | 1998 | 840 | 0.180 |
Why?
|
| Adolescent | 59 | 2015 | 87810 | 0.180 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 58995 | 0.180 |
Why?
|
| Schistosomiasis mansoni | 1 | 2021 | 94 | 0.180 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 382 | 0.180 |
Why?
|
| Disease-Free Survival | 9 | 2020 | 6828 | 0.180 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2002 | 438 | 0.180 |
Why?
|
| Peptides | 4 | 2020 | 4354 | 0.170 |
Why?
|
| Prednisolone | 1 | 2021 | 327 | 0.170 |
Why?
|
| Catechin | 1 | 2020 | 69 | 0.170 |
Why?
|
| Manganese Compounds | 1 | 2019 | 25 | 0.170 |
Why?
|
| Japan | 9 | 2005 | 1369 | 0.170 |
Why?
|
| Biopsy, Needle | 6 | 2016 | 1630 | 0.170 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2004 | 547 | 0.170 |
Why?
|
| Convalescence | 1 | 2020 | 106 | 0.170 |
Why?
|
| Diamines | 1 | 2019 | 59 | 0.170 |
Why?
|
| Picolinic Acids | 1 | 2019 | 50 | 0.170 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2022 | 829 | 0.170 |
Why?
|
| Vimentin | 4 | 2017 | 255 | 0.170 |
Why?
|
| Genetic Engineering | 7 | 2005 | 933 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2015 | 4899 | 0.170 |
Why?
|
| Cyclophosphamide | 2 | 2002 | 2221 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 10 | 2024 | 22023 | 0.160 |
Why?
|
| Mucin-1 | 1 | 2004 | 539 | 0.160 |
Why?
|
| Gelatinases | 1 | 1999 | 88 | 0.160 |
Why?
|
| Lung Neoplasms | 10 | 2015 | 13262 | 0.160 |
Why?
|
| STAT3 Transcription Factor | 2 | 2017 | 877 | 0.160 |
Why?
|
| Viruses | 2 | 2002 | 376 | 0.160 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 3 | 1997 | 80 | 0.160 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2018 | 72 | 0.160 |
Why?
|
| Thromboxane B2 | 3 | 1997 | 147 | 0.160 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 184 | 0.160 |
Why?
|
| HTLV-I Infections | 1 | 1998 | 103 | 0.150 |
Why?
|
| Anticarcinogenic Agents | 1 | 2020 | 249 | 0.150 |
Why?
|
| Manuscripts as Topic | 1 | 2018 | 15 | 0.150 |
Why?
|
| Piperazines | 3 | 2007 | 2525 | 0.150 |
Why?
|
| Antimetabolites | 1 | 1998 | 128 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 854 | 0.150 |
Why?
|
| Viral Proteins | 2 | 2002 | 1802 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2019 | 5253 | 0.150 |
Why?
|
| Palliative Care | 3 | 2020 | 3607 | 0.150 |
Why?
|
| Pneumonia, Pneumocystis | 2 | 1991 | 245 | 0.150 |
Why?
|
| Blood Transfusion | 3 | 1996 | 1328 | 0.150 |
Why?
|
| Transplantation Chimera | 3 | 2014 | 595 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 211 | 0.150 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 2418 | 0.150 |
Why?
|
| Blotting, Western | 9 | 2016 | 5039 | 0.150 |
Why?
|
| Creatinine | 13 | 2000 | 1903 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2016 | 3804 | 0.150 |
Why?
|
| Transfection | 9 | 2006 | 5781 | 0.150 |
Why?
|
| Liver Failure | 2 | 2019 | 249 | 0.140 |
Why?
|
| Thrombosis | 2 | 2023 | 3052 | 0.140 |
Why?
|
| Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
| Muromonab-CD3 | 2 | 2000 | 104 | 0.140 |
Why?
|
| Child | 45 | 2015 | 79806 | 0.140 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2005 | 938 | 0.140 |
Why?
|
| Gibberellins | 1 | 2016 | 8 | 0.140 |
Why?
|
| Cause of Death | 7 | 2019 | 3725 | 0.140 |
Why?
|
| Pyrus | 1 | 2016 | 13 | 0.140 |
Why?
|
| Fibrin | 1 | 2020 | 505 | 0.140 |
Why?
|
| Drug Combinations | 4 | 2018 | 2025 | 0.140 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2006 | 2049 | 0.140 |
Why?
|
| Cilazapril | 1 | 1996 | 3 | 0.140 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 1039 | 0.140 |
Why?
|
| Metalloendopeptidases | 1 | 1999 | 393 | 0.140 |
Why?
|
| Physical Exertion | 1 | 2020 | 662 | 0.140 |
Why?
|
| Ureteral Obstruction | 1 | 2019 | 292 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 12 | 2021 | 20509 | 0.140 |
Why?
|
| Extracellular Matrix | 4 | 2023 | 1726 | 0.140 |
Why?
|
| Chelating Agents | 1 | 2018 | 384 | 0.140 |
Why?
|
| Gliosarcoma | 1 | 1997 | 113 | 0.140 |
Why?
|
| Plant Growth Regulators | 1 | 2016 | 50 | 0.140 |
Why?
|
| Immunohistochemistry | 11 | 2016 | 11071 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2019 | 3016 | 0.140 |
Why?
|
| Lipogenesis | 1 | 2018 | 210 | 0.140 |
Why?
|
| Frizzled Receptors | 1 | 2017 | 90 | 0.140 |
Why?
|
| Injections, Intravenous | 3 | 2008 | 1385 | 0.140 |
Why?
|
| Catecholamines | 2 | 1996 | 385 | 0.140 |
Why?
|
| Keratan Sulfate | 1 | 1996 | 17 | 0.140 |
Why?
|
| Haplorhini | 4 | 2008 | 529 | 0.140 |
Why?
|
| Radiopharmaceuticals | 8 | 2024 | 2634 | 0.140 |
Why?
|
| Ligation | 2 | 2015 | 448 | 0.140 |
Why?
|
| Epitopes | 2 | 2000 | 2503 | 0.140 |
Why?
|
| Organophosphorus Compounds | 2 | 2016 | 202 | 0.130 |
Why?
|
| Genes, p53 | 1 | 1999 | 713 | 0.130 |
Why?
|
| Hepatocytes | 3 | 2024 | 1229 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2019 | 424 | 0.130 |
Why?
|
| Macrophages | 5 | 2022 | 5745 | 0.130 |
Why?
|
| Diagnostic Imaging | 2 | 2010 | 3527 | 0.130 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 1996 | 57 | 0.130 |
Why?
|
| Bile Ducts | 2 | 2015 | 282 | 0.130 |
Why?
|
| Cells, Cultured | 14 | 2015 | 18957 | 0.130 |
Why?
|
| Molecular Probes | 4 | 2022 | 313 | 0.130 |
Why?
|
| Glycoside Hydrolases | 1 | 1996 | 132 | 0.130 |
Why?
|
| Writing | 1 | 2018 | 199 | 0.130 |
Why?
|
| Pandemics | 3 | 2020 | 8624 | 0.130 |
Why?
|
| Dendritic Cells | 2 | 2006 | 2725 | 0.130 |
Why?
|
| Cell Adhesion | 7 | 2007 | 3094 | 0.130 |
Why?
|
| Hospitals, General | 1 | 2020 | 795 | 0.130 |
Why?
|
| Desmin | 2 | 2010 | 99 | 0.130 |
Why?
|
| Kidney Function Tests | 3 | 2015 | 681 | 0.130 |
Why?
|
| Ceramides | 1 | 2017 | 201 | 0.130 |
Why?
|
| Phosphoprotein Phosphatases | 3 | 2004 | 330 | 0.130 |
Why?
|
| Antigens, Viral | 2 | 1997 | 980 | 0.130 |
Why?
|
| Lymphocytes | 3 | 2020 | 2611 | 0.130 |
Why?
|
| Liver Circulation | 2 | 2008 | 159 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 951 | 0.130 |
Why?
|
| Risk Factors | 25 | 2020 | 74359 | 0.130 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2015 | 1355 | 0.120 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2015 | 29 | 0.120 |
Why?
|
| Ischemia | 1 | 2024 | 1893 | 0.120 |
Why?
|
| Cadherins | 4 | 2017 | 898 | 0.120 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 2138 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2010 | 550 | 0.120 |
Why?
|
| Photons | 1 | 2019 | 581 | 0.120 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2017 | 432 | 0.120 |
Why?
|
| Journal Impact Factor | 1 | 2016 | 156 | 0.120 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2017 | 574 | 0.120 |
Why?
|
| Thromboxane-A Synthase | 3 | 1989 | 34 | 0.120 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 388 | 0.120 |
Why?
|
| Models, Biological | 5 | 2021 | 9467 | 0.120 |
Why?
|
| Kidney Glomerulus | 4 | 2007 | 568 | 0.120 |
Why?
|
| Melanoma, Amelanotic | 1 | 2014 | 19 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 2 | 2004 | 5785 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 2 | 2017 | 944 | 0.120 |
Why?
|
| Tumor Burden | 5 | 2017 | 1895 | 0.120 |
Why?
|
| Antibody Specificity | 2 | 2015 | 1060 | 0.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2022 | 1523 | 0.120 |
Why?
|
| Lysophospholipids | 1 | 2016 | 339 | 0.120 |
Why?
|
| Hepacivirus | 3 | 2021 | 1334 | 0.120 |
Why?
|
| Splenectomy | 2 | 2011 | 391 | 0.120 |
Why?
|
| Recombinant Proteins | 7 | 2014 | 6538 | 0.120 |
Why?
|
| Hepatitis B virus | 2 | 2010 | 522 | 0.120 |
Why?
|
| Cell Proliferation | 7 | 2018 | 10446 | 0.120 |
Why?
|
| Neoplasm Transplantation | 4 | 2005 | 2014 | 0.110 |
Why?
|
| Biomimetics | 1 | 2015 | 173 | 0.110 |
Why?
|
| Prospective Studies | 14 | 2020 | 54303 | 0.110 |
Why?
|
| Steroids | 1 | 2019 | 928 | 0.110 |
Why?
|
| Galactosylceramides | 1 | 2014 | 92 | 0.110 |
Why?
|
| Complement C4b | 3 | 2007 | 132 | 0.110 |
Why?
|
| Mice, Inbred C3H | 2 | 2014 | 915 | 0.110 |
Why?
|
| Chronic Disease | 13 | 2011 | 9287 | 0.110 |
Why?
|
| Lipase | 1 | 2016 | 324 | 0.110 |
Why?
|
| Plasmodium falciparum | 4 | 2000 | 1742 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2005 | 2221 | 0.110 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 5889 | 0.110 |
Why?
|
| Neuroleptic Malignant Syndrome | 1 | 1994 | 74 | 0.110 |
Why?
|
| Clinical Trials as Topic | 7 | 2019 | 8056 | 0.110 |
Why?
|
| Organ Transplantation | 2 | 2020 | 1150 | 0.110 |
Why?
|
| Androgens | 1 | 2021 | 1291 | 0.110 |
Why?
|
| Pancreas | 1 | 2020 | 1677 | 0.110 |
Why?
|
| Organoplatinum Compounds | 2 | 2017 | 410 | 0.110 |
Why?
|
| Cell Division | 9 | 2003 | 4463 | 0.110 |
Why?
|
| Sputum | 2 | 1993 | 503 | 0.110 |
Why?
|
| New Zealand | 1 | 2014 | 355 | 0.110 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 1997 | 190 | 0.110 |
Why?
|
| Pentetic Acid | 1 | 1993 | 209 | 0.110 |
Why?
|
| Apoptosis | 10 | 2014 | 9501 | 0.110 |
Why?
|
| Tissue Distribution | 4 | 2019 | 2262 | 0.110 |
Why?
|
| Cadaver | 7 | 2008 | 1345 | 0.110 |
Why?
|
| Membrane Proteins | 6 | 2016 | 7850 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 1993 | 0.100 |
Why?
|
| Cisplatin | 2 | 2017 | 1644 | 0.100 |
Why?
|
| Myocardial Infarction | 7 | 1996 | 11891 | 0.100 |
Why?
|
| Nevus | 1 | 2014 | 205 | 0.100 |
Why?
|
| Kidney Diseases | 3 | 2019 | 2093 | 0.100 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 1993 | 135 | 0.100 |
Why?
|
| Immunotherapy | 6 | 2019 | 4642 | 0.100 |
Why?
|
| Sex Factors | 6 | 2020 | 10547 | 0.100 |
Why?
|
| Asia | 1 | 2014 | 620 | 0.100 |
Why?
|
| Thiazolidinediones | 2 | 2009 | 465 | 0.100 |
Why?
|
| Transcriptional Activation | 2 | 2022 | 1755 | 0.100 |
Why?
|
| Tooth Root | 1 | 2013 | 162 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2003 | 886 | 0.100 |
Why?
|
| Perfusion Imaging | 1 | 2013 | 196 | 0.100 |
Why?
|
| Glutarates | 1 | 2014 | 244 | 0.100 |
Why?
|
| Hemodynamics | 4 | 1997 | 4174 | 0.100 |
Why?
|
| Neoplasm Proteins | 5 | 2006 | 3610 | 0.100 |
Why?
|
| Age Distribution | 3 | 2007 | 2893 | 0.100 |
Why?
|
| Lupus Nephritis | 1 | 2015 | 318 | 0.100 |
Why?
|
| Communicable Diseases | 2 | 1998 | 878 | 0.100 |
Why?
|
| Molecular Sequence Data | 14 | 2000 | 17624 | 0.100 |
Why?
|
| Erythrocytes | 3 | 1998 | 2415 | 0.100 |
Why?
|
| Myocardial Reperfusion | 1 | 1993 | 347 | 0.100 |
Why?
|
| Liver Diseases | 1 | 2020 | 1302 | 0.100 |
Why?
|
| Periodontal Ligament | 2 | 2003 | 117 | 0.100 |
Why?
|
| DNA, Protozoan | 1 | 1992 | 228 | 0.100 |
Why?
|
| Acute Disease | 5 | 2017 | 7269 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2023 | 1943 | 0.100 |
Why?
|
| Pentamidine | 1 | 1991 | 44 | 0.090 |
Why?
|
| Risk Assessment | 9 | 2012 | 24123 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 1392 | 0.090 |
Why?
|
| Kidney Tubules | 4 | 2007 | 449 | 0.090 |
Why?
|
| Sex Distribution | 2 | 2007 | 2295 | 0.090 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 1304 | 0.090 |
Why?
|
| Fruit | 1 | 2016 | 1160 | 0.090 |
Why?
|
| Axilla | 1 | 2014 | 626 | 0.090 |
Why?
|
| Blood Grouping and Crossmatching | 3 | 1996 | 100 | 0.090 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1993 | 378 | 0.090 |
Why?
|
| Interleukins | 1 | 2016 | 785 | 0.090 |
Why?
|
| Complement C4 | 2 | 2004 | 244 | 0.090 |
Why?
|
| Child, Preschool | 19 | 2012 | 42063 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2015 | 664 | 0.090 |
Why?
|
| Antigens, CD20 | 1 | 2011 | 201 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2015 | 10827 | 0.090 |
Why?
|
| Carrier Proteins | 4 | 2007 | 4938 | 0.090 |
Why?
|
| Gene Expression Regulation | 4 | 2019 | 11903 | 0.090 |
Why?
|
| Basophils | 1 | 1993 | 404 | 0.090 |
Why?
|
| Yeasts | 1 | 2011 | 279 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 586 | 0.090 |
Why?
|
| Mutation | 11 | 2019 | 29932 | 0.090 |
Why?
|
| Renal Dialysis | 2 | 1998 | 1801 | 0.090 |
Why?
|
| Publishing | 1 | 2018 | 836 | 0.090 |
Why?
|
| DNA Primers | 4 | 2001 | 2819 | 0.090 |
Why?
|
| Iron | 1 | 2019 | 1786 | 0.090 |
Why?
|
| Necrosis | 4 | 2009 | 1612 | 0.090 |
Why?
|
| Case-Control Studies | 8 | 2013 | 22053 | 0.090 |
Why?
|
| Cholelithiasis | 1 | 2011 | 408 | 0.090 |
Why?
|
| Cytopathogenic Effect, Viral | 2 | 2002 | 151 | 0.090 |
Why?
|
| Liposomes | 1 | 2014 | 777 | 0.090 |
Why?
|
| Mammography | 3 | 2006 | 2427 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 2315 | 0.090 |
Why?
|
| Polyps | 1 | 2011 | 197 | 0.090 |
Why?
|
| Australia | 1 | 2014 | 1289 | 0.090 |
Why?
|
| Medical History Taking | 1 | 2014 | 773 | 0.090 |
Why?
|
| Incidence | 11 | 2019 | 21392 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2003 | 1046 | 0.090 |
Why?
|
| Antibodies | 3 | 1997 | 2421 | 0.090 |
Why?
|
| Benchmarking | 1 | 2016 | 1044 | 0.080 |
Why?
|
| Base Sequence | 8 | 2000 | 12446 | 0.080 |
Why?
|
| Patient Care Team | 2 | 2020 | 2511 | 0.080 |
Why?
|
| Chemoprevention | 2 | 2022 | 326 | 0.080 |
Why?
|
| Tissue and Organ Procurement | 1 | 1998 | 944 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 2828 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2014 | 632 | 0.080 |
Why?
|
| Oral Surgical Procedures | 1 | 2011 | 166 | 0.080 |
Why?
|
| Phosphorylation | 5 | 2018 | 8313 | 0.080 |
Why?
|
| Hypoglycemic Agents | 2 | 2018 | 3150 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2017 | 1347 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2023 | 3844 | 0.080 |
Why?
|
| T-Lymphocytes | 8 | 2017 | 10181 | 0.080 |
Why?
|
| Acyclovir | 1 | 1990 | 268 | 0.080 |
Why?
|
| Medical Oncology | 2 | 2019 | 2313 | 0.080 |
Why?
|
| Radionuclide Imaging | 6 | 2003 | 1975 | 0.080 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2018 | 1660 | 0.080 |
Why?
|
| Predictive Value of Tests | 7 | 2020 | 15289 | 0.080 |
Why?
|
| Lethal Dose 50 | 1 | 2008 | 72 | 0.080 |
Why?
|
| Antiviral Agents | 5 | 2016 | 3061 | 0.080 |
Why?
|
| Ischemic Preconditioning | 1 | 2009 | 89 | 0.080 |
Why?
|
| Reference Values | 5 | 2016 | 4925 | 0.080 |
Why?
|
| Down-Regulation | 3 | 2010 | 2913 | 0.080 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 375 | 0.080 |
Why?
|
| Melanocytes | 1 | 2012 | 512 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2019 | 2881 | 0.080 |
Why?
|
| Heterocyclic Compounds | 2 | 2020 | 247 | 0.080 |
Why?
|
| Colon | 2 | 1995 | 1788 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 693 | 0.080 |
Why?
|
| Extremities | 1 | 1994 | 867 | 0.080 |
Why?
|
| Inflammation | 4 | 2021 | 10756 | 0.080 |
Why?
|
| Sulfamethoxazole | 1 | 1988 | 53 | 0.080 |
Why?
|
| Treatment Failure | 5 | 2019 | 2648 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2010 | 4122 | 0.080 |
Why?
|
| Canada | 1 | 2014 | 2128 | 0.080 |
Why?
|
| Young Adult | 12 | 2016 | 58741 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2000 | 62 | 0.080 |
Why?
|
| Injections, Intraperitoneal | 1 | 2008 | 412 | 0.080 |
Why?
|
| Ultrasonography | 5 | 2011 | 5961 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 1613 | 0.080 |
Why?
|
| Metformin | 1 | 2016 | 912 | 0.080 |
Why?
|
| Capillaries | 3 | 2007 | 744 | 0.080 |
Why?
|
| Trimethoprim | 1 | 1988 | 84 | 0.080 |
Why?
|
| Random Allocation | 3 | 2017 | 2394 | 0.080 |
Why?
|
| Cell Cycle | 2 | 1995 | 2934 | 0.080 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1990 | 1544 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 221 | 0.080 |
Why?
|
| Caspases | 3 | 2006 | 878 | 0.070 |
Why?
|
| Genotype | 6 | 2017 | 12960 | 0.070 |
Why?
|
| Sirolimus | 1 | 2015 | 1547 | 0.070 |
Why?
|
| Preoperative Care | 4 | 2004 | 2256 | 0.070 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2011 | 640 | 0.070 |
Why?
|
| Receptors, Cell Surface | 2 | 1995 | 2825 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2017 | 1343 | 0.070 |
Why?
|
| DNA, Neoplasm | 4 | 1999 | 1745 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 1664 | 0.070 |
Why?
|
| Gabexate | 1 | 1987 | 12 | 0.070 |
Why?
|
| alpha-Cyclodextrins | 1 | 1987 | 12 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2010 | 1722 | 0.070 |
Why?
|
| Integrin alpha6beta1 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Neutrophils | 1 | 2020 | 3767 | 0.070 |
Why?
|
| Immunogenetics | 1 | 2007 | 66 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.070 |
Why?
|
| Urinary Tract Infections | 4 | 1997 | 814 | 0.070 |
Why?
|
| Oxygen Consumption | 8 | 1997 | 1843 | 0.070 |
Why?
|
| Exercise | 4 | 2020 | 5787 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 2180 | 0.070 |
Why?
|
| Respiration | 1 | 2013 | 1654 | 0.070 |
Why?
|
| Basement Membrane | 2 | 2007 | 348 | 0.070 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2017 | 345 | 0.070 |
Why?
|
| Heart Rate | 8 | 1998 | 4179 | 0.070 |
Why?
|
| Glutamine | 2 | 2002 | 576 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 1993 | 1602 | 0.070 |
Why?
|
| Collagen Type III | 1 | 2006 | 91 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2021 | 6544 | 0.070 |
Why?
|
| Decision Making | 1 | 2020 | 3925 | 0.070 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 268 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2020 | 3758 | 0.070 |
Why?
|
| Mohs Surgery | 1 | 2009 | 221 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2006 | 3484 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1998 | 374 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2007 | 384 | 0.070 |
Why?
|
| Sclerosis | 1 | 2006 | 210 | 0.070 |
Why?
|
| United States | 6 | 2021 | 72461 | 0.070 |
Why?
|
| Mice, Inbred ICR | 1 | 2006 | 364 | 0.070 |
Why?
|
| Methotrexate | 1 | 2013 | 1719 | 0.070 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 529 | 0.070 |
Why?
|
| Half-Life | 3 | 2017 | 652 | 0.070 |
Why?
|
| Patient Selection | 4 | 2008 | 4283 | 0.070 |
Why?
|
| Drug Resistance | 1 | 1992 | 1617 | 0.070 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 2 | 2001 | 325 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 278 | 0.060 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 254 | 0.060 |
Why?
|
| Salivary Glands | 1 | 2007 | 229 | 0.060 |
Why?
|
| Immunoglobulin A | 2 | 2007 | 979 | 0.060 |
Why?
|
| Blood Stains | 2 | 1996 | 8 | 0.060 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 380 | 0.060 |
Why?
|
| Angiogenic Proteins | 1 | 2006 | 101 | 0.060 |
Why?
|
| Amino Acid Sequence | 10 | 2000 | 13451 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2011 | 12965 | 0.060 |
Why?
|
| Rectum | 1 | 1990 | 895 | 0.060 |
Why?
|
| Gene Transfer, Horizontal | 1 | 2006 | 144 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2010 | 1652 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 10344 | 0.060 |
Why?
|
| Multivariate Analysis | 4 | 2021 | 12159 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 2016 | 1469 | 0.060 |
Why?
|
| Mass Screening | 3 | 2006 | 5423 | 0.060 |
Why?
|
| Postoperative Period | 5 | 2020 | 1818 | 0.060 |
Why?
|
| Allantois | 1 | 2004 | 33 | 0.060 |
Why?
|
| Morbidity | 2 | 2007 | 1765 | 0.060 |
Why?
|
| Mesoderm | 1 | 2008 | 672 | 0.060 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1987 | 687 | 0.060 |
Why?
|
| Hospitals, Veterans | 1 | 2007 | 398 | 0.060 |
Why?
|
| Gastroesophageal Reflux | 2 | 2009 | 816 | 0.060 |
Why?
|
| Antibodies, Viral | 1 | 1996 | 3143 | 0.060 |
Why?
|
| Antibody Formation | 3 | 2004 | 1400 | 0.060 |
Why?
|
| Administration, Oral | 3 | 2000 | 4035 | 0.060 |
Why?
|
| HLA Antigens | 3 | 2007 | 1368 | 0.060 |
Why?
|
| Cells | 1 | 2006 | 164 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2008 | 2448 | 0.060 |
Why?
|
| Dogs | 4 | 1994 | 3841 | 0.060 |
Why?
|
| Chorion | 1 | 2004 | 114 | 0.060 |
Why?
|
| Radiotherapy Dosage | 3 | 2018 | 2897 | 0.060 |
Why?
|
| Autophagy | 3 | 2009 | 1337 | 0.060 |
Why?
|
| Fluorine Radioisotopes | 1 | 2007 | 413 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2013 | 2488 | 0.060 |
Why?
|
| Gene Expression | 2 | 2015 | 7588 | 0.060 |
Why?
|
| Lamivudine | 1 | 2005 | 363 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2009 | 2852 | 0.060 |
Why?
|
| Glass Ionomer Cements | 1 | 2003 | 17 | 0.060 |
Why?
|
| Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
| DNA, Viral | 3 | 2002 | 2194 | 0.060 |
Why?
|
| Root Canal Filling Materials | 1 | 2003 | 29 | 0.060 |
Why?
|
| RNA, Messenger | 7 | 2015 | 12766 | 0.060 |
Why?
|
| Bone Marrow | 1 | 2014 | 2912 | 0.060 |
Why?
|
| Physical Conditioning, Animal | 1 | 2007 | 366 | 0.060 |
Why?
|
| Signal Transduction | 8 | 2021 | 23376 | 0.060 |
Why?
|
| Enzyme Induction | 3 | 1999 | 452 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 5 | 2007 | 2471 | 0.050 |
Why?
|
| Immunoblotting | 1 | 2006 | 1649 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 4550 | 0.050 |
Why?
|
| Massachusetts | 4 | 2021 | 8803 | 0.050 |
Why?
|
| Gadolinium DTPA | 2 | 2019 | 823 | 0.050 |
Why?
|
| Anus Neoplasms | 1 | 2007 | 329 | 0.050 |
Why?
|
| Nephrotic Syndrome | 1 | 2007 | 391 | 0.050 |
Why?
|
| Epoprostenol | 4 | 1988 | 248 | 0.050 |
Why?
|
| Tenascin | 1 | 2023 | 62 | 0.050 |
Why?
|
| Mesenteric Veins | 1 | 2023 | 85 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 3084 | 0.050 |
Why?
|
| Fluorescence | 2 | 2023 | 751 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 1996 | 516 | 0.050 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2004 | 186 | 0.050 |
Why?
|
| Protein Isoforms | 2 | 2015 | 1697 | 0.050 |
Why?
|
| Probability | 2 | 2005 | 2475 | 0.050 |
Why?
|
| Chi-Square Distribution | 3 | 2021 | 3465 | 0.050 |
Why?
|
| Immune Tolerance | 2 | 2006 | 2299 | 0.050 |
Why?
|
| Pyridines | 2 | 2019 | 2879 | 0.050 |
Why?
|
| Stem Cells | 1 | 2016 | 3523 | 0.050 |
Why?
|
| Newcastle disease virus | 1 | 2002 | 21 | 0.050 |
Why?
|
| Pregnancy Complications | 1 | 1997 | 2942 | 0.050 |
Why?
|
| Interferons | 3 | 2016 | 705 | 0.050 |
Why?
|
| Sarcoma | 1 | 1994 | 1786 | 0.050 |
Why?
|
| Saliva | 1 | 2007 | 820 | 0.050 |
Why?
|
| Clostridium Infections | 1 | 1989 | 557 | 0.050 |
Why?
|
| Transplantation, Autologous | 4 | 2013 | 2116 | 0.050 |
Why?
|
| Kinetics | 4 | 2018 | 6377 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 4573 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2013 | 4357 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5325 | 0.050 |
Why?
|
| Safety | 1 | 2007 | 1148 | 0.050 |
Why?
|
| Prostaglandins | 2 | 1997 | 398 | 0.050 |
Why?
|
| Proteins | 4 | 2006 | 6029 | 0.050 |
Why?
|
| Molecular Weight | 7 | 1995 | 2186 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2011 | 1588 | 0.050 |
Why?
|
| Autoantigens | 1 | 2006 | 877 | 0.050 |
Why?
|
| Chickens | 1 | 2004 | 860 | 0.050 |
Why?
|
| Fatty Acids | 1 | 1990 | 1804 | 0.050 |
Why?
|
| Cell Movement | 4 | 2017 | 5206 | 0.050 |
Why?
|
| Teratoma | 1 | 2005 | 403 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2018 | 3426 | 0.050 |
Why?
|
| Nizatidine | 1 | 2021 | 7 | 0.050 |
Why?
|
| DNA Nucleotidyltransferases | 3 | 1982 | 176 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 2007 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2005 | 618 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2008 | 3602 | 0.050 |
Why?
|
| Sialoglycoproteins | 2 | 2003 | 315 | 0.050 |
Why?
|
| Reoviridae | 1 | 2002 | 162 | 0.050 |
Why?
|
| Delirium | 1 | 1994 | 1663 | 0.050 |
Why?
|
| Protein Folding | 1 | 2006 | 867 | 0.050 |
Why?
|
| Micelles | 1 | 2022 | 192 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2005 | 329 | 0.050 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 12531 | 0.050 |
Why?
|
| Exercise Test | 4 | 2007 | 2128 | 0.050 |
Why?
|
| Consensus | 2 | 2022 | 3113 | 0.050 |
Why?
|
| Intraoperative Care | 3 | 2004 | 768 | 0.050 |
Why?
|
| Vascular Diseases | 2 | 1987 | 1182 | 0.050 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 907 | 0.050 |
Why?
|
| Benzamides | 1 | 2007 | 1369 | 0.050 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 1130 | 0.050 |
Why?
|
| HeLa Cells | 3 | 2000 | 3105 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2002 | 336 | 0.050 |
Why?
|
| Age Factors | 8 | 2021 | 18416 | 0.050 |
Why?
|
| Logistic Models | 3 | 2011 | 13314 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 2 | 2001 | 548 | 0.050 |
Why?
|
| Eukaryotic Initiation Factor-2 | 1 | 2002 | 180 | 0.050 |
Why?
|
| Chromans | 1 | 2001 | 117 | 0.050 |
Why?
|
| Immunologic Surveillance | 1 | 2021 | 92 | 0.050 |
Why?
|
| Rats, Inbred Lew | 2 | 1996 | 1154 | 0.050 |
Why?
|
| Fever | 3 | 2001 | 1617 | 0.050 |
Why?
|
| Cell Death | 2 | 2006 | 1672 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 1999 | 356 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 4353 | 0.050 |
Why?
|
| Coloring Agents | 3 | 2001 | 562 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2001 | 189 | 0.050 |
Why?
|
| Retreatment | 2 | 2016 | 600 | 0.050 |
Why?
|
| Blood Pressure | 6 | 1998 | 8525 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2022 | 14660 | 0.050 |
Why?
|
| Immunosorbent Techniques | 2 | 2000 | 176 | 0.050 |
Why?
|
| Hydrazines | 1 | 2022 | 224 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2002 | 326 | 0.050 |
Why?
|
| Acrosome | 1 | 2000 | 10 | 0.050 |
Why?
|
| Zona Pellucida | 1 | 2000 | 14 | 0.050 |
Why?
|
| Sperm-Ovum Interactions | 1 | 2000 | 23 | 0.050 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2001 | 100 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 361 | 0.040 |
Why?
|
| Flavoproteins | 1 | 2000 | 40 | 0.040 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2000 | 135 | 0.040 |
Why?
|
| Permeability | 1 | 2022 | 719 | 0.040 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2007 | 5251 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 1988 | 981 | 0.040 |
Why?
|
| Infant | 8 | 2001 | 36060 | 0.040 |
Why?
|
| Chalcones | 1 | 2020 | 29 | 0.040 |
Why?
|
| Nephrectomy | 2 | 2004 | 1016 | 0.040 |
Why?
|
| Pancreatitis | 2 | 2019 | 1100 | 0.040 |
Why?
|
| Phenotype | 5 | 2020 | 16546 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2002 | 343 | 0.040 |
Why?
|
| Cytokines | 2 | 2014 | 7343 | 0.040 |
Why?
|
| Schistosoma mansoni | 1 | 2021 | 156 | 0.040 |
Why?
|
| Cell Membrane | 3 | 2006 | 3682 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2005 | 559 | 0.040 |
Why?
|
| Radiography | 2 | 2010 | 6965 | 0.040 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2000 | 83 | 0.040 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2001 | 179 | 0.040 |
Why?
|
| Glucose Tolerance Test | 2 | 2009 | 1175 | 0.040 |
Why?
|
| Models, Statistical | 2 | 2005 | 5075 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2008 | 1475 | 0.040 |
Why?
|
| Lysine | 1 | 2024 | 1001 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 1994 | 2859 | 0.040 |
Why?
|
| Forearm | 2 | 2005 | 429 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2002 | 629 | 0.040 |
Why?
|
| Immunosorbents | 2 | 1998 | 21 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 2000 | 297 | 0.040 |
Why?
|
| Propionates | 1 | 2020 | 182 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2000 | 140 | 0.040 |
Why?
|
| Bacterial Infections | 2 | 1998 | 1403 | 0.040 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2000 | 166 | 0.040 |
Why?
|
| Immune Sera | 3 | 1995 | 613 | 0.040 |
Why?
|
| Isoniazid | 1 | 2001 | 283 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2023 | 987 | 0.040 |
Why?
|
| Succinate Dehydrogenase | 1 | 2000 | 145 | 0.040 |
Why?
|
| Transcription, Genetic | 3 | 2002 | 7593 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 3202 | 0.040 |
Why?
|
| Actins | 1 | 2006 | 2049 | 0.040 |
Why?
|
| Recurrence | 7 | 2012 | 8482 | 0.040 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2005 | 63 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 656 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1988 | 2197 | 0.040 |
Why?
|
| 4-Aminobenzoic Acid | 2 | 1989 | 22 | 0.040 |
Why?
|
| Phyllodes Tumor | 1 | 1999 | 52 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 491 | 0.040 |
Why?
|
| Rifampin | 1 | 2001 | 340 | 0.040 |
Why?
|
| Brain Death | 1 | 2002 | 356 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2006 | 1959 | 0.040 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 1998 | 40 | 0.040 |
Why?
|
| Drug Hypersensitivity | 1 | 1988 | 916 | 0.040 |
Why?
|
| Gene Targeting | 1 | 2002 | 839 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 2 | 1998 | 416 | 0.040 |
Why?
|
| Acetates | 1 | 2000 | 321 | 0.040 |
Why?
|
| Histocompatibility | 2 | 1998 | 316 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 829 | 0.040 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 1998 | 38 | 0.040 |
Why?
|
| Hepatitis C | 2 | 2021 | 1579 | 0.040 |
Why?
|
| Neoplasms, Experimental | 3 | 2001 | 1229 | 0.040 |
Why?
|
| Amines | 1 | 2000 | 281 | 0.040 |
Why?
|
| Atrial Natriuretic Factor | 2 | 1996 | 350 | 0.040 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1999 | 221 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 673 | 0.040 |
Why?
|
| Attitude to Health | 2 | 2004 | 2029 | 0.040 |
Why?
|
| Oxidopamine | 1 | 1998 | 172 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2019 | 127 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2001 | 549 | 0.040 |
Why?
|
| Mannose | 2 | 1989 | 121 | 0.040 |
Why?
|
| Tea | 1 | 2020 | 284 | 0.040 |
Why?
|
| Asthma | 3 | 1993 | 6172 | 0.040 |
Why?
|
| Electrodes | 1 | 2001 | 614 | 0.040 |
Why?
|
| Precancerous Conditions | 2 | 2020 | 977 | 0.040 |
Why?
|
| Transplantation, Heterotopic | 1 | 2018 | 174 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3562 | 0.040 |
Why?
|
| Porphyrins | 1 | 2000 | 353 | 0.040 |
Why?
|
| Cell Line | 7 | 2019 | 15620 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 861 | 0.040 |
Why?
|
| Lymphokines | 1 | 2001 | 927 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2007 | 2118 | 0.040 |
Why?
|
| Standard of Care | 1 | 2022 | 552 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2002 | 658 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2006 | 2210 | 0.040 |
Why?
|
| Radioimmunoassay | 2 | 1997 | 866 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 1055 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 397 | 0.040 |
Why?
|
| Leukocyte Count | 2 | 2020 | 1600 | 0.040 |
Why?
|
| Proteinuria | 2 | 2001 | 594 | 0.040 |
Why?
|
| Acrylates | 2 | 1987 | 79 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 1999 | 228 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 389 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 777 | 0.040 |
Why?
|
| Radio Waves | 1 | 1999 | 250 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2021 | 1456 | 0.040 |
Why?
|
| Schistosoma japonicum | 1 | 1997 | 5 | 0.040 |
Why?
|
| Laminin | 1 | 1999 | 405 | 0.040 |
Why?
|
| Monocytes | 1 | 2006 | 2575 | 0.040 |
Why?
|
| Methacrylates | 2 | 1987 | 109 | 0.040 |
Why?
|
| Blotting, Southern | 2 | 2000 | 777 | 0.040 |
Why?
|
| Norepinephrine | 2 | 1998 | 900 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2001 | 675 | 0.040 |
Why?
|
| Mice, Knockout | 3 | 2021 | 14372 | 0.040 |
Why?
|
| Gene Transfer Techniques | 1 | 2002 | 1204 | 0.040 |
Why?
|
| Iliac Artery | 1 | 1998 | 344 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2024 | 1089 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2001 | 711 | 0.040 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 103 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2002 | 1347 | 0.030 |
Why?
|
| Thiazoles | 2 | 2001 | 1511 | 0.030 |
Why?
|
| Insulin | 3 | 2009 | 6597 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2008 | 3663 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2023 | 1189 | 0.030 |
Why?
|
| Skin | 1 | 2010 | 4466 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 3 | 2007 | 2882 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 1999 | 461 | 0.030 |
Why?
|
| Choline | 1 | 2018 | 513 | 0.030 |
Why?
|
| Tropomyosin | 1 | 1997 | 104 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2007 | 2754 | 0.030 |
Why?
|
| Renal Artery | 1 | 1998 | 370 | 0.030 |
Why?
|
| Cohort Studies | 5 | 2021 | 41335 | 0.030 |
Why?
|
| Photosynthesis | 1 | 2016 | 71 | 0.030 |
Why?
|
| Antimanic Agents | 1 | 2000 | 520 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2012 | 573 | 0.030 |
Why?
|
| Anilides | 1 | 2019 | 409 | 0.030 |
Why?
|
| Elbow | 1 | 1997 | 130 | 0.030 |
Why?
|
| ROC Curve | 2 | 2015 | 3568 | 0.030 |
Why?
|
| Herpes Simplex | 1 | 2000 | 478 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2007 | 4024 | 0.030 |
Why?
|
| Plant Leaves | 1 | 2016 | 151 | 0.030 |
Why?
|
| Peritoneal Lavage | 1 | 1996 | 30 | 0.030 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 701 | 0.030 |
Why?
|
| Vaccination | 2 | 2000 | 3361 | 0.030 |
Why?
|
| Exercise Therapy | 3 | 1995 | 919 | 0.030 |
Why?
|
| Medical Illustration | 1 | 1997 | 135 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 1996 | 231 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2001 | 1021 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 1998 | 451 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 2 | 1995 | 1343 | 0.030 |
Why?
|
| Glycosylation | 2 | 1996 | 1096 | 0.030 |
Why?
|
| Hypertension, Renovascular | 1 | 1996 | 117 | 0.030 |
Why?
|
| Spermatozoa | 1 | 2000 | 631 | 0.030 |
Why?
|
| Plant Lectins | 1 | 1996 | 103 | 0.030 |
Why?
|
| Radiation Chimera | 1 | 1995 | 216 | 0.030 |
Why?
|
| Proteomics | 2 | 2023 | 3817 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 1997 | 516 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1996 | 321 | 0.030 |
Why?
|
| alpha Catenin | 1 | 1995 | 37 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1997 | 383 | 0.030 |
Why?
|
| Pancreatectomy | 1 | 2020 | 810 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 301 | 0.030 |
Why?
|
| Transplants | 1 | 1998 | 206 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2000 | 782 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 1913 | 0.030 |
Why?
|
| Heat-Shock Proteins | 2 | 1992 | 795 | 0.030 |
Why?
|
| Hexosamines | 2 | 1992 | 40 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 2000 | 1529 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2017 | 207 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 232 | 0.030 |
Why?
|
| Weight Lifting | 1 | 1995 | 126 | 0.030 |
Why?
|
| Ligands | 2 | 2019 | 3276 | 0.030 |
Why?
|
| Interleukin-6 | 2 | 2014 | 3215 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 600 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 1998 | 983 | 0.030 |
Why?
|
| Heart Arrest | 2 | 2002 | 1506 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 1996 | 243 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 1996 | 575 | 0.030 |
Why?
|
| Pregnancy | 1 | 1997 | 29749 | 0.030 |
Why?
|
| Copper | 1 | 2017 | 368 | 0.030 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 1999 | 321 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1995 | 814 | 0.030 |
Why?
|
| Phytohemagglutinins | 1 | 1994 | 168 | 0.030 |
Why?
|
| Lung | 2 | 2023 | 9994 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1998 | 924 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2017 | 5201 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 1998 | 987 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2010 | 11481 | 0.030 |
Why?
|
| Genetic Variation | 3 | 2009 | 6551 | 0.030 |
Why?
|
| Antigens | 1 | 2000 | 1447 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2001 | 831 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2020 | 1440 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2001 | 1479 | 0.030 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 1994 | 65 | 0.030 |
Why?
|
| beta Catenin | 1 | 2019 | 1043 | 0.030 |
Why?
|
| Adipocytes | 1 | 2001 | 1179 | 0.030 |
Why?
|
| Quinolines | 1 | 2019 | 759 | 0.030 |
Why?
|
| Occupational Health | 1 | 2020 | 805 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 2 | 2007 | 105 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2000 | 1132 | 0.030 |
Why?
|
| Cloning, Molecular | 3 | 2000 | 4169 | 0.030 |
Why?
|
| Puerperal Disorders | 1 | 1997 | 300 | 0.030 |
Why?
|
| Cell Survival | 3 | 2015 | 5797 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 669 | 0.030 |
Why?
|
| Photochemotherapy | 1 | 2000 | 820 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3164 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 1246 | 0.030 |
Why?
|
| Cryosurgery | 1 | 1999 | 475 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 387 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2014 | 222 | 0.030 |
Why?
|
| Thymus Gland | 3 | 1985 | 1247 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 1997 | 4407 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2015 | 1088 | 0.030 |
Why?
|
| Rats, Inbred Strains | 3 | 1990 | 2094 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1996 | 480 | 0.030 |
Why?
|
| Injections | 1 | 1996 | 830 | 0.030 |
Why?
|
| Cytoplasm | 2 | 1995 | 1516 | 0.030 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1998 | 643 | 0.030 |
Why?
|
| Lymphedema | 1 | 2000 | 524 | 0.030 |
Why?
|
| Bicuspid | 1 | 2013 | 69 | 0.030 |
Why?
|
| Triage | 1 | 2020 | 987 | 0.030 |
Why?
|
| Glycosaminoglycans | 1 | 1996 | 605 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1998 | 1187 | 0.030 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1993 | 117 | 0.030 |
Why?
|
| Forecasting | 1 | 2002 | 2932 | 0.030 |
Why?
|
| Odontogenesis | 1 | 2013 | 65 | 0.030 |
Why?
|
| Foot | 1 | 1997 | 573 | 0.030 |
Why?
|
| Levodopa | 1 | 1994 | 217 | 0.030 |
Why?
|
| Collagenases | 1 | 1993 | 221 | 0.030 |
Why?
|
| Acetylglucosamine | 1 | 1994 | 189 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 8158 | 0.030 |
Why?
|
| Pulse | 1 | 1993 | 218 | 0.030 |
Why?
|
| RNA, Catalytic | 1 | 1993 | 53 | 0.030 |
Why?
|
| Periodontal Attachment Loss | 1 | 2013 | 144 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 2222 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 5508 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2003 | 2001 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2001 | 930 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2000 | 949 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 1837 | 0.030 |
Why?
|
| Adiponectin | 1 | 2018 | 1115 | 0.030 |
Why?
|
| Water | 1 | 2019 | 1407 | 0.030 |
Why?
|
| Endothelium, Vascular | 2 | 2007 | 4433 | 0.030 |
Why?
|
| Equipment Design | 1 | 2001 | 3520 | 0.030 |
Why?
|
| Eosinophils | 2 | 1998 | 944 | 0.030 |
Why?
|
| Naphthalenes | 1 | 1993 | 198 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 2012 | 110 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2001 | 1373 | 0.030 |
Why?
|
| Cattle | 6 | 1998 | 3847 | 0.030 |
Why?
|
| Clone Cells | 1 | 1996 | 1660 | 0.030 |
Why?
|
| Hypothermia, Induced | 1 | 1998 | 758 | 0.030 |
Why?
|
| Staining and Labeling | 2 | 1995 | 1089 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1993 | 192 | 0.030 |
Why?
|
| Molar | 1 | 2013 | 156 | 0.030 |
Why?
|
| Cholecystolithiasis | 1 | 2011 | 7 | 0.030 |
Why?
|
| Radiation Injuries | 1 | 2019 | 1183 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2007 | 613 | 0.030 |
Why?
|
| Angioplasty, Balloon | 1 | 1996 | 597 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2013 | 124 | 0.030 |
Why?
|
| rho-Associated Kinases | 3 | 1998 | 281 | 0.030 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 112 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2021 | 4264 | 0.030 |
Why?
|
| Crystallization | 1 | 1993 | 533 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 1996 | 969 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1993 | 700 | 0.020 |
Why?
|
| Renin-Angiotensin System | 1 | 1996 | 738 | 0.020 |
Why?
|
| Substantia Nigra | 1 | 1994 | 350 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 2 | 1997 | 2693 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2017 | 2627 | 0.020 |
Why?
|
| Interphase | 2 | 1998 | 228 | 0.020 |
Why?
|
| Razoxane | 1 | 1991 | 43 | 0.020 |
Why?
|
| Aldosterone | 1 | 1996 | 868 | 0.020 |
Why?
|
| Calcium | 2 | 1998 | 5725 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 801 | 0.020 |
Why?
|
| Hand | 1 | 1997 | 903 | 0.020 |
Why?
|
| Endothelial Cells | 3 | 2012 | 3539 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1996 | 1754 | 0.020 |
Why?
|
| Reoperation | 2 | 2018 | 4291 | 0.020 |
Why?
|
| Microcomputers | 1 | 1992 | 141 | 0.020 |
Why?
|
| Dental Clinics | 1 | 2011 | 30 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 1995 | 959 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 2 | 2009 | 1132 | 0.020 |
Why?
|
| Mitochondria | 2 | 2006 | 3600 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1991 | 96 | 0.020 |
Why?
|
| Hepatitis B | 1 | 1997 | 701 | 0.020 |
Why?
|
| Tooth Loss | 1 | 2013 | 198 | 0.020 |
Why?
|
| DNA Probes | 1 | 1992 | 551 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2019 | 1596 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2015 | 1617 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 778 | 0.020 |
Why?
|
| Fatigue | 1 | 1998 | 1544 | 0.020 |
Why?
|
| Lauric Acids | 1 | 1990 | 9 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 15840 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1628 | 0.020 |
Why?
|
| Thymoma | 2 | 1983 | 187 | 0.020 |
Why?
|
| Administration, Rectal | 1 | 1990 | 70 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1997 | 1484 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 2192 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2001 | 2698 | 0.020 |
Why?
|
| Malaria, Falciparum | 1 | 1998 | 1076 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7806 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| Linear Models | 1 | 2000 | 5877 | 0.020 |
Why?
|
| Length of Stay | 1 | 2004 | 6479 | 0.020 |
Why?
|
| Amino Acids | 1 | 1996 | 1714 | 0.020 |
Why?
|
| Flow Cytometry | 3 | 2013 | 5870 | 0.020 |
Why?
|
| Protein Kinases | 1 | 1997 | 1612 | 0.020 |
Why?
|
| Survivors | 1 | 2000 | 2375 | 0.020 |
Why?
|
| Glucuronosyltransferase | 1 | 1990 | 130 | 0.020 |
Why?
|
| Caprylates | 1 | 1990 | 113 | 0.020 |
Why?
|
| Microglia | 1 | 1998 | 1351 | 0.020 |
Why?
|
| DNA | 2 | 1996 | 7233 | 0.020 |
Why?
|
| Hemolysis | 1 | 1991 | 423 | 0.020 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 1 | 2010 | 70 | 0.020 |
Why?
|
| Clostridium | 1 | 1989 | 100 | 0.020 |
Why?
|
| Biological Availability | 1 | 1990 | 395 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 2011 | 406 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2020 | 2985 | 0.020 |
Why?
|
| Osteopontin | 2 | 2003 | 302 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3765 | 0.020 |
Why?
|
| Cell Nucleus | 3 | 2006 | 2907 | 0.020 |
Why?
|
| Serum Albumin | 1 | 1992 | 674 | 0.020 |
Why?
|
| Biological Assay | 1 | 1992 | 630 | 0.020 |
Why?
|
| Gallstones | 1 | 2011 | 283 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 1989 | 248 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1958 | 0.020 |
Why?
|
| Indoles | 1 | 2017 | 1829 | 0.020 |
Why?
|
| Myocardium | 4 | 1998 | 4700 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1996 | 1927 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 1484 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 2895 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1989 | 291 | 0.020 |
Why?
|
| Mathematics | 1 | 2009 | 707 | 0.020 |
Why?
|
| 3T3 Cells | 2 | 2001 | 1085 | 0.020 |
Why?
|
| Aerosols | 1 | 1991 | 632 | 0.020 |
Why?
|
| Biological Factors | 1 | 1989 | 157 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 1993 | 593 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2016 | 6238 | 0.020 |
Why?
|
| Leukocytes | 1 | 1996 | 2026 | 0.020 |
Why?
|
| General Surgery | 2 | 1997 | 1678 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1996 | 1974 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1741 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 1989 | 825 | 0.020 |
Why?
|
| Genes, ras | 1 | 2010 | 655 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 3 | 1998 | 7408 | 0.020 |
Why?
|
| Salmonella | 1 | 1988 | 126 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 1997 | 2272 | 0.020 |
Why?
|
| Arterioles | 1 | 2008 | 250 | 0.020 |
Why?
|
| Immunoglobulin G | 2 | 1997 | 4541 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 830 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2012 | 510 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1987 | 134 | 0.020 |
Why?
|
| Caveolae | 1 | 2007 | 55 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 3726 | 0.020 |
Why?
|
| Research | 1 | 1996 | 1974 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 3446 | 0.020 |
Why?
|
| Benzamidines | 1 | 1987 | 23 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2013 | 1411 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2017 | 1977 | 0.020 |
Why?
|
| Mast-Cell Sarcoma | 1 | 1986 | 46 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2000 | 3218 | 0.020 |
Why?
|
| Cyclodextrins | 1 | 1987 | 65 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2010 | 1155 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 1996 | 2145 | 0.020 |
Why?
|
| Cardiomegaly | 1 | 1989 | 593 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2016 | 17790 | 0.020 |
Why?
|
| Fibroblasts | 3 | 2002 | 4090 | 0.020 |
Why?
|
| Esters | 1 | 1987 | 211 | 0.020 |
Why?
|
| Aromatase | 1 | 2006 | 147 | 0.020 |
Why?
|
| Mast Cells | 1 | 1993 | 1390 | 0.020 |
Why?
|
| Glutathione Transferase | 2 | 1998 | 565 | 0.020 |
Why?
|
| Wood | 1 | 1986 | 91 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2006 | 152 | 0.020 |
Why?
|
| Heart | 1 | 1998 | 4393 | 0.020 |
Why?
|
| Ethanol | 1 | 1992 | 1323 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 2000 | 4312 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 2234 | 0.020 |
Why?
|
| Antimalarials | 1 | 1992 | 906 | 0.020 |
Why?
|
| Bronchi | 1 | 1989 | 848 | 0.020 |
Why?
|
| Catalysis | 2 | 2000 | 775 | 0.020 |
Why?
|
| Biological Transport | 2 | 2002 | 2086 | 0.020 |
Why?
|
| Ticlopidine | 2 | 1987 | 895 | 0.020 |
Why?
|
| Sesquiterpenes | 1 | 2006 | 176 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 2006 | 389 | 0.020 |
Why?
|
| Catheterization | 2 | 2002 | 1432 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 1997 | 3455 | 0.020 |
Why?
|
| Pyuria | 2 | 1997 | 30 | 0.010 |
Why?
|
| S100 Proteins | 1 | 2005 | 218 | 0.010 |
Why?
|
| Hemophilia A | 1 | 1988 | 359 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1995 | 3022 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 2414 | 0.010 |
Why?
|
| Electrocardiography | 2 | 1996 | 6414 | 0.010 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 490 | 0.010 |
Why?
|
| Rectal Neoplasms | 1 | 1993 | 1152 | 0.010 |
Why?
|
| Muscle, Skeletal | 2 | 1997 | 4925 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2009 | 1135 | 0.010 |
Why?
|
| Private Sector | 1 | 2007 | 397 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 575 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 1997 | 3880 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 1007 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2011 | 3615 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2007 | 2558 | 0.010 |
Why?
|
| Zinc Oxide-Eugenol Cement | 1 | 2003 | 9 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2006 | 956 | 0.010 |
Why?
|
| Bacteriuria | 2 | 1997 | 103 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1997 | 3201 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 1998 | 2873 | 0.010 |
Why?
|
| Protein Binding | 1 | 1995 | 9335 | 0.010 |
Why?
|
| Arteries | 1 | 2008 | 1126 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2019 | 8035 | 0.010 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2002 | 16 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2000 | 5078 | 0.010 |
Why?
|
| Plasmids | 1 | 1988 | 2275 | 0.010 |
Why?
|
| Cultural Characteristics | 1 | 2004 | 253 | 0.010 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2002 | 72 | 0.010 |
Why?
|
| Diathermy | 1 | 2002 | 17 | 0.010 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 1023 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2006 | 1095 | 0.010 |
Why?
|
| Growth Substances | 1 | 1985 | 768 | 0.010 |
Why?
|
| Fructosamine | 2 | 1992 | 14 | 0.010 |
Why?
|
| Rest | 1 | 2007 | 914 | 0.010 |
Why?
|
| Body Weight | 2 | 2009 | 4611 | 0.010 |
Why?
|
| Postmortem Changes | 2 | 1992 | 119 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1982 | 66 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 1996 | 3865 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 1996 | 3075 | 0.010 |
Why?
|
| Diet | 1 | 2020 | 8010 | 0.010 |
Why?
|
| Microscopy | 1 | 2007 | 885 | 0.010 |
Why?
|
| Floxuridine | 1 | 2001 | 43 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2002 | 293 | 0.010 |
Why?
|
| Tetrazolium Salts | 1 | 2001 | 92 | 0.010 |
Why?
|
| Astrocytoma | 2 | 1997 | 775 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2001 | 122 | 0.010 |
Why?
|
| Oxygen | 1 | 1993 | 4193 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1990 | 2417 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1993 | 4563 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2007 | 1035 | 0.010 |
Why?
|
| Chromatography, Affinity | 3 | 1992 | 534 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 1543 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2013 | 3905 | 0.010 |
Why?
|
| Technetium | 1 | 2001 | 321 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2006 | 838 | 0.010 |
Why?
|
| Chlorophyllides | 1 | 2000 | 54 | 0.010 |
Why?
|
| Acrosome Reaction | 1 | 2000 | 7 | 0.010 |
Why?
|
| Models, Animal | 1 | 2007 | 2117 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1985 | 1167 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2006 | 1791 | 0.010 |
Why?
|
| DNA Damage | 2 | 2006 | 2442 | 0.010 |
Why?
|
| Carcinoma, Embryonal | 1 | 2000 | 37 | 0.010 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2001 | 155 | 0.010 |
Why?
|
| Waiting Lists | 1 | 2005 | 763 | 0.010 |
Why?
|
| Mitomycin | 1 | 2001 | 262 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2000 | 144 | 0.010 |
Why?
|
| Osteoprotegerin | 1 | 2001 | 177 | 0.010 |
Why?
|
| DNA Replication | 2 | 1988 | 1412 | 0.010 |
Why?
|
| Angiography | 2 | 2002 | 1605 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1994 | 5523 | 0.010 |
Why?
|
| Boston | 1 | 2012 | 9280 | 0.010 |
Why?
|
| Materials Testing | 1 | 2003 | 862 | 0.010 |
Why?
|
| Etoposide | 1 | 2001 | 630 | 0.010 |
Why?
|
| Gamma Rays | 1 | 2001 | 317 | 0.010 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 1999 | 30 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 1351 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 748 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2001 | 522 | 0.010 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1983 | 491 | 0.010 |
Why?
|
| Algorithms | 2 | 2013 | 13981 | 0.010 |
Why?
|
| Sulfonylurea Compounds | 1 | 2001 | 221 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2006 | 1313 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 5791 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1998 | 3735 | 0.010 |
Why?
|
| Thymus Neoplasms | 1 | 1982 | 274 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 1055 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 2000 | 482 | 0.010 |
Why?
|
| Marine Toxins | 1 | 1998 | 24 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1998 | 67 | 0.010 |
Why?
|
| Cross Reactions | 2 | 1994 | 818 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 119 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1998 | 317 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 585 | 0.010 |
Why?
|
| Anaphase | 1 | 1998 | 116 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1999 | 280 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1998 | 213 | 0.010 |
Why?
|
| Phosphoserine | 1 | 1998 | 203 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2001 | 335 | 0.010 |
Why?
|
| Physicians | 1 | 1996 | 4591 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 1998 | 134 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 1997 | 1717 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 563 | 0.010 |
Why?
|
| Occupational Diseases | 1 | 1986 | 1486 | 0.010 |
Why?
|
| Software | 1 | 1992 | 4419 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 237 | 0.010 |
Why?
|
| Intermediate Filaments | 1 | 1998 | 172 | 0.010 |
Why?
|
| Kidney Papillary Necrosis | 1 | 1997 | 3 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2000 | 330 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1998 | 426 | 0.010 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1997 | 87 | 0.010 |
Why?
|
| Guanosine Triphosphate | 1 | 1998 | 316 | 0.010 |
Why?
|
| Guanosine Diphosphate | 1 | 1997 | 80 | 0.010 |
Why?
|
| Gamma Cameras | 1 | 1997 | 34 | 0.010 |
Why?
|
| Decision Trees | 1 | 1999 | 506 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1998 | 183 | 0.010 |
Why?
|
| Hypertriglyceridemia | 1 | 2000 | 316 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1997 | 187 | 0.010 |
Why?
|
| Oxazoles | 1 | 1998 | 199 | 0.010 |
Why?
|
| Furans | 1 | 1998 | 199 | 0.010 |
Why?
|
| Educational Status | 1 | 2004 | 2515 | 0.010 |
Why?
|
| Cystitis | 1 | 1997 | 96 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1998 | 230 | 0.010 |
Why?
|
| Punctures | 1 | 1998 | 370 | 0.010 |
Why?
|
| rho GTP-Binding Proteins | 1 | 1998 | 277 | 0.010 |
Why?
|
| Vasculitis | 1 | 2001 | 523 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2000 | 943 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1997 | 328 | 0.010 |
Why?
|
| Leukemia | 1 | 1985 | 1520 | 0.010 |
Why?
|
| Antigens, Protozoan | 1 | 1998 | 316 | 0.010 |
Why?
|
| Cricetinae | 1 | 2000 | 2427 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1996 | 361 | 0.010 |
Why?
|
| Thymidine | 1 | 1996 | 299 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1996 | 306 | 0.010 |
Why?
|
| Vasopressins | 1 | 1998 | 355 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 330 | 0.010 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 157 | 0.010 |
Why?
|
| Protein Phosphatase 2 | 1 | 1998 | 236 | 0.010 |
Why?
|
| COS Cells | 1 | 1998 | 1129 | 0.010 |
Why?
|
| Chromatography | 1 | 1996 | 189 | 0.010 |
Why?
|
| Culture Media | 1 | 1998 | 900 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1997 | 433 | 0.010 |
Why?
|
| Blood Platelets | 1 | 1987 | 2520 | 0.010 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1997 | 102 | 0.010 |
Why?
|
| Phosphopeptides | 1 | 1997 | 241 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2000 | 2176 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1996 | 5870 | 0.010 |
Why?
|
| Caspase 3 | 1 | 1998 | 731 | 0.010 |
Why?
|
| Heart Failure | 2 | 1997 | 11847 | 0.010 |
Why?
|
| Aneurysm | 1 | 1998 | 337 | 0.010 |
Why?
|
| Detergents | 1 | 1996 | 235 | 0.010 |
Why?
|
| Oocytes | 1 | 2000 | 1165 | 0.010 |
Why?
|
| Chimera | 1 | 1996 | 453 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 755 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2000 | 786 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 1997 | 900 | 0.010 |
Why?
|
| Receptors, Interleukin-6 | 1 | 1996 | 226 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1997 | 838 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1996 | 630 | 0.010 |
Why?
|
| Rabbits | 1 | 2001 | 4773 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2001 | 1268 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1998 | 1608 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2002 | 1238 | 0.010 |
Why?
|
| Arteriosclerosis | 1 | 1999 | 1064 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 9631 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1998 | 1098 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 651 | 0.010 |
Why?
|
| Tanzania | 1 | 1998 | 1383 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2014 | 12103 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2000 | 1817 | 0.010 |
Why?
|
| Chloromercuribenzoates | 1 | 1973 | 5 | 0.010 |
Why?
|
| Candida albicans | 1 | 1997 | 374 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2000 | 935 | 0.010 |
Why?
|
| Pathology | 1 | 1997 | 270 | 0.010 |
Why?
|
| Polycyclic Compounds | 1 | 1993 | 29 | 0.010 |
Why?
|
| Lectins | 1 | 1996 | 484 | 0.010 |
Why?
|
| Mercaptoethanol | 1 | 1973 | 63 | 0.010 |
Why?
|
| Ethylmaleimide | 1 | 1973 | 70 | 0.010 |
Why?
|
| Nuclear Medicine | 1 | 1997 | 236 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1973 | 95 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1995 | 8986 | 0.010 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 951 | 0.010 |
Why?
|
| Blood Preservation | 1 | 1994 | 168 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2000 | 1124 | 0.010 |
Why?
|
| Hypercholesterolemia | 1 | 2000 | 1155 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 1993 | 72 | 0.010 |
Why?
|
| Brain | 3 | 1998 | 26951 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1973 | 299 | 0.010 |
Why?
|
| Tetrahymena | 1 | 1993 | 10 | 0.010 |
Why?
|
| Templates, Genetic | 1 | 1973 | 189 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 1973 | 189 | 0.010 |
Why?
|
| Perfusion | 1 | 1998 | 1376 | 0.010 |
Why?
|
| Tritium | 1 | 1973 | 707 | 0.010 |
Why?
|
| Rats, Inbred BUF | 2 | 1983 | 19 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1997 | 1792 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 1993 | 143 | 0.010 |
Why?
|
| Electrochemistry | 1 | 1993 | 143 | 0.010 |
Why?
|
| Hot Temperature | 2 | 1992 | 1435 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1973 | 645 | 0.010 |
Why?
|
| Triglycerides | 1 | 2000 | 2476 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1994 | 513 | 0.010 |
Why?
|
| Solubility | 1 | 1994 | 1088 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1993 | 818 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2002 | 1413 | 0.010 |
Why?
|
| Fertilization in Vitro | 1 | 2000 | 1292 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 1998 | 1972 | 0.010 |
Why?
|
| Diketopiperazines | 1 | 1991 | 24 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1996 | 12293 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1993 | 617 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 2000 | 1439 | 0.010 |
Why?
|
| Molecular Conformation | 1 | 1993 | 548 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1996 | 1428 | 0.010 |
Why?
|
| Cholesterol | 1 | 2000 | 2924 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 20080 | 0.010 |
Why?
|
| Colorimetry | 1 | 1991 | 153 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1992 | 238 | 0.010 |
Why?
|
| Sodium | 1 | 1996 | 1594 | 0.010 |
Why?
|
| Mitral Valve Stenosis | 1 | 1993 | 348 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 1973 | 493 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1993 | 614 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2001 | 2629 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 1997 | 1548 | 0.010 |
Why?
|
| Cell Separation | 1 | 1996 | 1720 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1997 | 2362 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 1993 | 632 | 0.010 |
Why?
|
| Geriatrics | 2 | 1965 | 387 | 0.010 |
Why?
|
| Aging | 1 | 2009 | 8651 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 1989 | 151 | 0.010 |
Why?
|
| Family | 1 | 2000 | 3189 | 0.010 |
Why?
|
| Autopsy | 1 | 1973 | 1007 | 0.010 |
Why?
|
| Tissue Extracts | 1 | 1989 | 140 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1989 | 394 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1989 | 239 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2000 | 4713 | 0.010 |
Why?
|
| Deoxyribonuclease EcoRI | 1 | 1988 | 31 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1993 | 1199 | 0.000 |
Why?
|
| Prostaglandins E | 1 | 1988 | 169 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1973 | 2502 | 0.000 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1989 | 309 | 0.000 |
Why?
|
| Bilirubin | 1 | 1990 | 438 | 0.000 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1988 | 217 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1988 | 553 | 0.000 |
Why?
|
| Atrophy | 1 | 1973 | 1627 | 0.000 |
Why?
|
| Registries | 1 | 2004 | 8469 | 0.000 |
Why?
|
| Organ Size | 1 | 1993 | 2254 | 0.000 |
Why?
|
| RNA, Viral | 1 | 1996 | 2838 | 0.000 |
Why?
|
| Swine | 1 | 1998 | 5899 | 0.000 |
Why?
|
| Lung Diseases | 1 | 1998 | 1915 | 0.000 |
Why?
|
| Respiratory Hypersensitivity | 1 | 1989 | 272 | 0.000 |
Why?
|
| Alleles | 1 | 1998 | 6898 | 0.000 |
Why?
|
| Astrocytes | 1 | 1995 | 1338 | 0.000 |
Why?
|
| Regression Analysis | 1 | 1996 | 6360 | 0.000 |
Why?
|
| Myocardial Ischemia | 1 | 1997 | 2164 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1989 | 849 | 0.000 |
Why?
|
| Mitosis | 1 | 1991 | 1191 | 0.000 |
Why?
|
| Deer | 1 | 1985 | 14 | 0.000 |
Why?
|
| Bacteria | 1 | 1997 | 2199 | 0.000 |
Why?
|
| Cerebellum | 1 | 1973 | 1496 | 0.000 |
Why?
|
| RNA Splicing | 1 | 1990 | 915 | 0.000 |
Why?
|
| Dinoprostone | 1 | 1988 | 598 | 0.000 |
Why?
|
| Mice, Inbred AKR | 1 | 1985 | 104 | 0.000 |
Why?
|
| Transforming Growth Factors | 1 | 1985 | 75 | 0.000 |
Why?
|
| Sulfobromophthalein | 1 | 1964 | 9 | 0.000 |
Why?
|
| Septum Pellucidum | 1 | 1965 | 54 | 0.000 |
Why?
|
| Hypoproteinemia | 1 | 1964 | 12 | 0.000 |
Why?
|
| Chemistry | 1 | 1985 | 348 | 0.000 |
Why?
|
| Endothelium | 1 | 1987 | 764 | 0.000 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1996 | 2128 | 0.000 |
Why?
|
| Chemical Phenomena | 1 | 1985 | 508 | 0.000 |
Why?
|
| Virulence | 1 | 1988 | 1298 | 0.000 |
Why?
|
| Binding Sites | 1 | 1993 | 6048 | 0.000 |
Why?
|
| Walking | 1 | 1990 | 1189 | 0.000 |
Why?
|
| DNA, Bacterial | 1 | 1988 | 1456 | 0.000 |
Why?
|
| Angiocardiography | 1 | 1962 | 153 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1993 | 5434 | 0.000 |
Why?
|
| Cerebral Ventricles | 1 | 1965 | 542 | 0.000 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1991 | 1547 | 0.000 |
Why?
|
| Wounds, Stab | 1 | 1962 | 72 | 0.000 |
Why?
|
| Laparotomy | 1 | 1964 | 465 | 0.000 |
Why?
|
| Islets of Langerhans | 1 | 1988 | 1345 | 0.000 |
Why?
|
| Chymotrypsin | 1 | 1981 | 138 | 0.000 |
Why?
|
| Smoking | 1 | 1998 | 9073 | 0.000 |
Why?
|
| Trypsin | 1 | 1981 | 496 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 2001 | 26181 | 0.000 |
Why?
|
| Depression | 1 | 2000 | 8044 | 0.000 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1985 | 1077 | 0.000 |
Why?
|
| Heart Injuries | 1 | 1962 | 208 | 0.000 |
Why?
|
| Glioblastoma | 1 | 1995 | 3484 | 0.000 |
Why?
|
| Gastrectomy | 1 | 1965 | 679 | 0.000 |
Why?
|
| Microtubules | 1 | 1985 | 1072 | 0.000 |
Why?
|
| Cysts | 1 | 1965 | 683 | 0.000 |
Why?
|
| Energy Metabolism | 1 | 1990 | 2869 | 0.000 |
Why?
|
| Computer Simulation | 1 | 1993 | 6218 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1981 | 1433 | 0.000 |
Why?
|
| Fibroblast Growth Factors | 1 | 1985 | 869 | 0.000 |
Why?
|
| Species Specificity | 1 | 1981 | 2418 | 0.000 |
Why?
|
| Cerebral Cortex | 1 | 1973 | 5761 | 0.000 |
Why?
|
| Hypertension | 1 | 1996 | 8594 | 0.000 |
Why?
|
| Gastrointestinal Diseases | 1 | 1964 | 1190 | 0.000 |
Why?
|
| Anemia | 1 | 1964 | 1511 | 0.000 |
Why?
|
| Sepsis | 1 | 1989 | 2592 | 0.000 |
Why?
|
| Surgical Procedures, Operative | 1 | 1964 | 1913 | 0.000 |
Why?
|